Table 3.
Retrospective cohort comparison of progression to severe COVID-19 between the EBV-positive and EBV-negative groups.
| EBV-negative (n = 224) | P-value | ||
| COVID-19 severity | COVID-19 severity | n (%) | |
| Gr1 | Gr1 | 182 (81.3%) | |
| Gr2 | Gr2 | 36 (16.7%) | |
| Gr3 | Gr3 | 6 (2.7%) | |
| Gr4 | Gr4 | 0 (0.0%) | |
| Gr5 | Gr5 | 0 (0.0%) | |
| Gr6 | Gr6 | 0 (0.0%) | |
| Moderate-severe (Gr2–6) | Moderate-severe (Gr2–6) | 42 (18.8%) | .04∗ |
| Severe (Gr3–6) | Severe (Gr3–6) | 7 (3.1%) | .003∗ |
EBV = Epstein–Barr virus, Gr1, Grade 1 = symptomatic but no oxygen therapy required, Gr2, Grade 2 = low-flow nasal cannula, Gr3, Grade 3 = high-flow nasal cannula/non-invasive ventilation, Gr4, Grade 4 = mechanical ventilation, Gr5, Grade 5 = extracorporeal membrane oxygenation, Gr6, Grade 6 = death.